Medicare to broaden coverage for new Alzheimer's drugs after full approval

The U.S. Medicare health plan said on Thursday it would limit reimbursement for Eisai Co Ltd and Biogen Inc's Alzheimer's drug Leqembi to patients whose doctors participate in a health agency database should the drug win full approval, a move advocates say will hinder its use.

Related Keywords

United States ,Bengaluru ,Karnataka ,India ,Americans ,Pooja Desai ,Shounak Dasgupta ,Manas Mishra ,Biogen Inc Biibo Leqembi ,Centers For Medicare Medicaid Services ,Reuters ,Drug Administration ,Eisai Co Ltd ,Thomson Reuters Trust Principles ,Biogen Inc ,Medicaid Services ,Thomson Reuters Trust ,Rhpi Biopharma ,Bioph ,Blr ,Cmpny ,Dement ,Gen ,Hea ,Heca ,Humdis ,Mrch ,Neurol ,Phag08 ,Phar ,Phar08 ,Phar1 ,Phmr ,Publ ,Gamers ,Us ,Namer ,Topnws ,Rsbi Regulatory Oversight ,Rhpi Drug Device Trials ,Rhpi Regulatory ,Bact ,Biz ,Cprod ,Drudev ,Fin ,Fins ,Fins08 ,Genhlt ,Insr ,Medreg ,Regs ,Easia ,Asxpac ,Asia ,Jp ,Ef Business Future Of Health ,Rhpi Public Health ,Pubhea ,Mtpix ,Advo ,Ngo ,Sci ,Topcmb ,